



# Financial Tear Sheet

## Corporate Profile

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. Our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations.

## Primary IR Contact

**Phone:** 617-674-1872

**E-mail:** kevin@enumeral.com


## Stock Performance

### ENUM (COMMON STOCK)

|                     |                    |
|---------------------|--------------------|
| <b>Exchange</b>     | OTC BB (US Dollar) |
| <b>Price</b>        | <b>\$0.00</b>      |
| <b>Change (%)</b>   | 0.00 (NaN%)        |
| <b>Volume</b>       | 0                  |
| <b>52 Week High</b> | \$0.00             |
| <b>52 Week Low</b>  | \$0.00             |
| <b>Market Cap</b>   | \$449,434          |
| <b>Rolling EPS</b>  | 0.00               |
| <b>PE Ratio</b>     | 0                  |

**Shares Outstanding** 128,409,788

Data as of 02/02/18 4:00 p.m. ET



## Recent Headlines & Events

08/14/17 - 5:00 p.m.

Enumeral Reports Second Quarter Financial Results

05/22/17 - 4:31 p.m.

Enumeral Reports First Quarter Financial Results

04/05/17 - 7:50 a.m.

Enumeral and ICAV to Pursue Infectious Disease Collaboration

There are currently no events scheduled.

# SEC Filings

| FILING DATE | FORM     |
|-------------|----------|
| 02/13/18    | SC 13G/A |
| 01/29/18    | 8-K      |
| 01/29/18    | 424B3    |
| 01/12/18    | SC 13G/A |

# Corporate Governance

John J. Rydzewski  
Executive Chairman of the Board of Directors and Co-Founder

Arthur H. Tinkelenberg, Ph.D.  
President, Chief Executive Officer, Director and Co-Founder

Kevin Sarney  
Vice President of Finance and Chief Accounting Officer

M. Isabel Chiu, Ph.D.  
Vice President of Translational and Clinical Sciences

Anhco  
"Cokey" Nguyen, Ph.D.  
Vice President of Research and Development

Derek Brand  
Vice President of Business Development

Matthew A. Ebert  
General Counsel

Gary L. Creason, Ph.D.  
Vice President of Intellectual Property

# Ownership Summary

## SHAREHOLDERS

|             | Holders | Value (\$MM) | % O/S | Shares     |
|-------------|---------|--------------|-------|------------|
| Institution | 11      | 1.99         | 19.4  | 24,923,272 |
| Mutual Fund | 0       | .00          | 0.0   | 0          |
| Insider *   | 7       | .47          | 2.7   | 3,401,418  |

\*Insider values reflect direct beneficial ownership.

## TOP HOLDERS

|                           | Shares Held | % O/S | Share Change | Filing Date |
|---------------------------|-------------|-------|--------------|-------------|
| Peierls (E Jeffrey)       | 10,890,080  | 8.5   | 10,890,080   | 12/31/16    |
| Satterfield (Thomas A Jr) | 6,419,200   | 5.0   | 0            | 12/31/17    |
| 180 Degree Capital Corp   | 3,455,368   | 2.7   | -4,511,000   | 08/11/17    |
| Rothstein (Allan P)       | 2,024,415   | 1.6   | 200,000      | 03/24/17    |
| Peierls (Brian Eliot)     | 581,920     | 0.5   | 581,920      | 12/31/16    |
| Easton (Robert J)         | 480,000     | 0.4   | 480,000      | 03/24/17    |
| Fayad (Wael)              | 298,000     | 0.2   | 298,000      | 03/24/17    |
| Buckland (Barry John)     | 296,168     | 0.2   | 52,000       | 03/24/17    |
| Van Nostrand (Robert L)   | 268,121     | 0.2   | 222,666      | 03/24/17    |
| Sekhri (Paul J)           | 175,000     | 0.1   | 175,000      | 03/24/17    |

Data provided by Nasdaq. Minimum 15 minutes delayed.